iNOS aggravates pressure overload-induced cardiac dysfunction via activation of the cytosolic-mtDNA-mediated

Yongzheng Guo1, Yuehua You1, Fei-Fei Shang2

  • 1Division of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.

Theranostics
|August 9, 2023
PubMed

Insights

Inducible nitric oxide synthase (iNOS) drives mitochondrial DNA release and sterile inflammation via the cGAS-STING pathway, worsening cardiac dysfunction in pressure overload. Blocking this pathway improves heart function.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Molecular Medicine

Background:

  • Sterile inflammation is key in cardiac dysfunction from pressure overload.
  • Mitochondrial DNA (mtDNA) release is implicated, but its triggers and inflammatory pathways are unclear.
  • Investigating inducible nitric oxide synthase (iNOS) and the cGAS-STING pathway in this context.

Purpose of the Study:

  • To determine if iNOS controls mtDNA release and sterile inflammation in pressure-overloaded hearts.
  • To elucidate the role of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway in pressure overload-induced cardiac dysfunction.
  • To assess the therapeutic potential of targeting the iNOS-mtDNA-cGAS-STING axis.

Main Methods:

  • Utilized transverse aortic constriction (TAC) in iNOS knockout and cardiomyocyte-specific STING-depleted mice.
  • Employed adeno-associated virus-9 (AAV-9) to suppress cardiac cGAS-STING signaling.
  • Analyzed cytosolic mtDNA, inflammatory markers, macrophage polarization, and cardiac function.

Main Results:

  • iNOS knockout prevented mtDNA release, reduced sterile inflammation, and improved cardiac function post-TAC.
  • Activation of the cGAS-STING pathway counteracted iNOS knockout's protective effects.
  • iNOS promoted cGAS-STING activation, which was dependent on cytosolic mtDNA; this axis drives inflammation and cardiac dysfunction, observed also in human hypertension.

Conclusions:

  • Pressure overload induces sterile inflammation and cardiac dysfunction via iNOS-mediated mtDNA release activating the cGAS-STING pathway.
  • Targeting iNOS or the cGAS-STING pathway holds promise for treating pressure overload-induced heart conditions.
  • Findings reveal a novel mechanism linking iNOS, mtDNA, and innate immunity in hypertensive heart disease.

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
9
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.7K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
622
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11